Is Salesforce.com (CRM) a Buy as Wall Street Analysts Look Optimistic?

Salesforce.com (CRM) currently holds an average brokerage recommendation (ABR) of 1.52, approximating a 'Buy,' based on ratings from 48 brokerage firms, with 75% of recommendations as 'Strong Buy'; however, the article suggests that investors should not rely solely on ABR due to potential biases from brokerage firms. The Zacks Rank, driven by earnings estimate revisions, is presented as a potentially more reliable indicator, and Salesforce.com currently holds a Zacks Rank #3 (Hold), with the consensus earnings estimate unchanged over the past month at $11.12, suggesting near-term performance in line with the broader market.

Analysis

Salesforce.com (CRM) exhibits a strong Average Brokerage Recommendation (ABR) of 1.52, positioning it between a Strong Buy and Buy, with 81.3% of the 48 covering brokerage firms recommending either a Strong Buy (75%) or Buy (6.3%). However, the article cautions against relying solely on ABR due to inherent positive biases in sell-side analyst ratings stemming from brokerage firms' vested interests. In contrast, the Zacks Rank, a proprietary model driven by earnings estimate revisions, assigns CRM a #3 (Hold). This more neutral stance is supported by the Zacks Consensus Estimate for Salesforce.com's current year earnings, which has remained unchanged at $11.12 over the past month. Such stability in earnings estimates suggests that the stock is likely to perform in line with the broader market in the near term. The overall sentiment is mixed with a cautious tone, reflecting the divergence between the optimistic ABR and the more tempered outlook provided by the Zacks Rank and static earnings estimates.

Key Decisions for Investors

• Investors should exercise caution and not solely rely on the optimistic Average Brokerage Recommendation for Salesforce.com, given the potential for sell-side analyst bias.
• Consider the Zacks Rank #3 (Hold) and the unchanged consensus earnings estimate of $11.12 as indicators that CRM may offer near-term performance aligned with the broader market, rather than significant outperformance implied by the ABR.
• It is prudent to validate the ABR with independent research and quantitative indicators like the Zacks Rank and trends in earnings estimate revisions before making investment decisions regarding CRM.